23 Jul, 2026
According to Straits Research, the global endoscopic retrograde cholangiopancreatography market valued at $2.33 billion in 2025, is projected to grow from $2.52 billion in 2026 to $4.74 billion by 2034 at a CAGR of 8.21% during the forecast period 2026–2034.
Endoscopic retrograde cholangiopancreatography, or ERCP, is a diagnostic and therapeutic procedure that uses upper gastrointestinal (GI) endoscopy and X-ray imaging to diagnose and treat conditions affecting the bile and pancreatic ducts. Bile ducts are the tubes that carry bile from the liver to the gallbladder and then to the duodenum. Pancreatic juice is moved through these channels from the duodenum to the pancreas. A doctor might advise an ERCP procedure when bile or pancreatic ducts have narrowed or blocked. This could be brought on by bile duct and pancreatic cancers, infection, acute or chronic pancreatitis, pancreatic pseudocysts, or gallstones.
ERCP is a diagnostic procedure for gallbladder, biliary system, pancreas, and liver diseases. ERCP devices utilize a combination of fluoroscopic imaging and luminal endoscopy to diagnose and treat pancreaticobiliary system disorders. Endotherapy devices are frequently utilized to treat Barrett's disease, biliary disease, colitis, Crohn's disease, gastroesophageal reflux disease (GERD), liver disease, pancreatitis, inflammatory bowel disease, and peptic ulcer disease. Endotherapy devices are sphincterotomy, guidewire, balloon, basket, lithotripters, stent, grasping forceps, cannula, and single-use balloon dilator.
The prevalence of chronic diseases has increased, with Barrett's Disease, Biliary Disease, Colitis, Crohn's Disease, Gastroesophageal Reflux Disorder (GERD), liver Disease, Pancreatitis, Inflammatory Bowel Disease, and Peptic Ulcer Disease being the most prevalent. When the bile ducts are blocked or terminal gallstones form in the Ogallala, this type of surgery is necessary to drain bile from the liver. Chronic gastrointestinal and biliary conditions are the most prevalent conditions that make it difficult for patients to perform daily tasks. The market for endoscopic retrograde cholangiopancreatography is anticipated to grow as a result of a rise in the prevalence of diseases, which will subsequently increase the demand for treatment.
The endoscopic retrograde cholangiopancreatography market is experiencing a rapid and continuous increase in devices for diagnosing comorbidities such as adenomas, hemangiomas, and focal nodular hyperplasia (FNH), Pancreatic adenocarcinoma, Ampullary cancer, Adenosquamous, carcinomas, Pancreatic cysts, Barrett's Disease., Biliary Disease, Colitis, Crohn's Disease A rise in disorders associated with the pancreas, liver, and bile duct has led to an increase in awareness of ERCP devices. This provides manufacturers with growth opportunities, thereby stimulating market expansion.
In the region, endoscopes, endotherapy devices, imaging systems, and energy devices are used in most endoscopic retrograde cholangiopancreatography (ERCP) procedures in the United States. This is expected to present a sizable opportunity for companies in the endoscopic retrograde cholangiopancreatography market to expand their clientele and earnings. The second-most lucrative market for ERCP is Europe. The significant harmful impact bile explains this and biliary disorders have on people's general health.
sales@straitsresearch.com